← All trials
NCT06214793
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2024
- Primary completion
- Jan 1, 2030
- Completion date
- Jan 1, 2030
- First posted
- Jan 22, 2024
- Last posted
- Aug 9, 2024
- Enrollment
- 61
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Case Western Reserve UniversityLead sponsor
- The Cleveland ClinicOfficial
- Case Western Reserve UniversitySponsor investigator
- AnHeart Therapeutics Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.